Clinical trials: Magnetic Resonance Imaging Contrast Agents
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with…
- Trial name
- LUMINA (NCT07472491)
- Testing
- Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
- Where
- 7 sites in United States, Georgia and 2 more
- Volunteers
- 640 people
- Sponsor
- GE Healthcare
Breast Cancer, Breast Diseases
Contrast-Free Magnetic Resonance Imaging for Breast Disease
Prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast MRI.
- Trial name
- IMOGEN (NCT05006196)
- Testing
- Outpatient MRI
- Where
- United Kingdom
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Perspectum
Contrast-Enhanced Magnetic Resonance Imaging Detection
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study. The primary objectives are: To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single…
- Trial name
- NCT06657560
- Testing
- HRS-9231
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Vascular Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.
- Trial name
- NCT00395733
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadopentate dimeglumine (Magnevist, BAY86-4882)
- Where
- 3 sites in China
- Volunteers
- 83 people
- Sponsor
- Bayer
Renal Artery Stenosis
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the renal arteries.
- Trial name
- NCT00310557
- Testing
- Gadopentetate dimeglumine (Magnevist)
- Volunteers
- 116 people
- Sponsor
- Bayer
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: the safety of BAY1747846 when given at increasing single doses…
- Trial name
- NCT06125366
- Testing
- BAY1747846
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Peripheral Vascular Diseases
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a…
- Trial name
- NCT00296855
- Testing
- Vasovist (BAY86-5283, MS-325)
- Where
- 26 sites in Argentina, Austria and 4 more
- Volunteers
- 261 people
- Sponsor
- Bayer